Merck’s (NYSE: MRK) Q3 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q3 worldwide sales of $17.3 billion.
“In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches,” said Rob Davis, chairman and CEO. “We’re delivering value to patients and customers through our innovative portfolio of medicines and vaccines, and we’re securing our future by making important investments in our pipeline — including through compelling, strategic business development like our completed acquisition of Verona Pharma and expanded U.S. manufacturing and R&D spending. With each milestone we achieve, my conviction that we’re well-positioned to drive the next chapter of success for our company increases.”
Merck anticipates full-year 2025 worldwide sales to be between $64.5 billion and $65.0 billion.
Take a look at the infographic below for more details on Q3 2025 results.
